findmyKOL

Thomas Olenginski, MD

Basic profile

Geisinger Health System

ORCIDNone on fileNPI
RegionDanville, PA · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Thomas Olenginski is a Rheumatology/Immunology physician affiliated with Geisinger Health System. OpenAlex indexes 38 publications with 995 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
38publications

Distinct works indexed by OpenAlex.

995citations

Total citations across indexed works.

15h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    28.5%
    Folate Analog Metabolic Inhibitor13.9%
    Methotrexate100%
    Part D48 patients
    TNF inhibitor10.5%
    Humira Pen32%Enbrel27%Enbrel Sureclick23%Humira18%
    Part D<11 patients

    + 3 more classes in this area

  • Hormonal (systemic)

    22.8%
    Parathyroid Hormone Analog15.7%
    Teriparatide70%Forteo30%
    Part D21 patients
    Parathyroid Hormone-Related Peptide Analog7.1%
    Tymlos100%
    Part D13 patients
  • Musculoskeletal

    13.8%
    Xanthine oxidase inhibitor7.5%
    Allopurinol100%
    Part D29 patients
    Nonsteroidal Anti-inflammatory Drug2.6%
    Diclofenac Sodium66%Nabumetone34%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)87.7% facility · 12.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”